Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. uri icon

authors

  • Courtney, Kevin D
  • Wallace, Eli M
  • Josey, John A
  • Choueiri, Toni K
  • Infante, Jeffrey R
  • Lam, Elaine T
  • Figlin, Robert A
  • Rini, Brian I
  • Brugarolas, James
  • Zojwalla, Naseem J
  • Lowe, Ann M
  • Wang, Keshi

publication date

  • January 1, 2017